GENENTECH NUTROPIN AND LILLY HUMATROPE PHASE IV TURNER's SYNDROME STUDIES SHOULD INCLUDE TREATMENT OPTIMIZATION; NEW hGH INDICATION RECOMMENDED
Executive Summary
Lilly and Genentech should conduct post-marketing studies to optimize treatment and assess the long-term safety of their human growth hormone products in Turner's syndrome, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended at its Dec. 10 meeting.